BMRN Key Statistics, Chart & Performance
The current stock price of BMRN is 55.93 USD. In the past month the price increased by 7.74%. In the past year, price decreased by -15.3%.
BMRN Latest News, Press Relases and Analysis
BMRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About BMRN
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Company Info
BIOMARIN PHARMACEUTICAL INC
770 Lindaro Street
San Rafael California CALIFORNIA 94901 US
CEO: Jean-Jacques Bienaime
Employees: 3040
Phone: 14155066700
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you describe the business of BIOMARIN PHARMACEUTICAL INC?
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Can you provide the latest stock price for BIOMARIN PHARMACEUTICAL INC?
The current stock price of BMRN is 55.93 USD. The price increased by 0.74% in the last trading session.
What is the dividend status of BIOMARIN PHARMACEUTICAL INC?
BMRN does not pay a dividend.
What is the ChartMill rating of BIOMARIN PHARMACEUTICAL INC stock?
BMRN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for BMRN stock?
34 analysts have analysed BMRN and the average price target is 94.11 USD. This implies a price increase of 68.26% is expected in the next year compared to the current price of 55.93.
What is the market capitalization of BMRN stock?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a market capitalization of 10.74B USD. This makes BMRN a Large Cap stock.
When does BIOMARIN PHARMACEUTICAL INC (BMRN) report earnings?
BIOMARIN PHARMACEUTICAL INC (BMRN) will report earnings on 2026-02-17, after the market close.
BMRN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to BMRN. When comparing the yearly performance of all stocks, BMRN is a bad performer in the overall market: 75% of all stocks are doing better.
BMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BMRN. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
BMRN Financial Highlights
Over the last trailing twelve months BMRN reported a non-GAAP Earnings per Share(EPS) of 2.66. The EPS increased by 52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.82% | ||
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| Debt/Equity | 0.1 |
BMRN Forecast & Estimates
34 analysts have analysed BMRN and the average price target is 94.11 USD. This implies a price increase of 68.26% is expected in the next year compared to the current price of 55.93.
For the next year, analysts expect an EPS growth of 37.42% and a revenue growth 12.45% for BMRN